Illumina, Inc. (NASDAQ:ILMN) Shares Purchased by Creative Planning

Creative Planning lifted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 3.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,679 shares of the life sciences company’s stock after purchasing an additional 535 shares during the quarter. Creative Planning’s holdings in Illumina were worth $2,175,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Illumina by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 18,245,041 shares of the life sciences company’s stock worth $2,505,409,000 after purchasing an additional 66,528 shares in the last quarter. Baillie Gifford & Co. lifted its position in Illumina by 8.7% during the 1st quarter. Baillie Gifford & Co. now owns 5,736,418 shares of the life sciences company’s stock worth $787,725,000 after acquiring an additional 460,649 shares during the period. Bank of New York Mellon Corp lifted its position in Illumina by 7.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 3,039,538 shares of the life sciences company’s stock worth $317,267,000 after acquiring an additional 204,043 shares during the period. Capital World Investors lifted its position in Illumina by 41.1% during the 1st quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company’s stock worth $378,111,000 after acquiring an additional 801,814 shares during the period. Finally, Primecap Management Co. CA lifted its position in Illumina by 462.5% during the 2nd quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock worth $253,514,000 after acquiring an additional 1,997,010 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

ILMN has been the subject of a number of research reports. JPMorgan Chase & Co. lowered their price target on Illumina from $130.00 to $125.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Scotiabank lowered their price target on Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a research report on Thursday, August 15th. Robert W. Baird lifted their price target on Illumina from $119.00 to $124.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Hsbc Global Res raised Illumina from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 17th. Finally, Piper Sandler decreased their price objective on Illumina from $200.00 to $195.00 and set an “overweight” rating for the company in a report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $154.33.

Illumina Stock Up 0.4 %

NASDAQ:ILMN opened at $141.95 on Monday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 1.04. The stock’s fifty day moving average is $134.53 and its two-hundred day moving average is $121.57. Illumina, Inc. has a 52 week low of $89.00 and a 52 week high of $151.40. The stock has a market capitalization of $22.61 billion, a price-to-earnings ratio of -7.41 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.24. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The company had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same period in the prior year, the firm earned $0.32 earnings per share. The firm’s revenue was down 5.4% compared to the same quarter last year. Research analysts anticipate that Illumina, Inc. will post 3.63 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.